{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:43:29Z","timestamp":1776087809255,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Obesity associates with reduced life expectancy, type 2 diabetes, hypertension and cardiovascular disease, and is characterized by chronic inflammation. Phosphorylcholine (PC) is an epitope on oxidized low-density lipoprotein, dead cells and some microorganisms. Antibodies against PC (anti-PC) have anti-inflammatory properties. Here, we explored the role of anti-PC in hospitalized versus non-hospitalized obese. One-hundred-and-twenty-eight obese (BMI\u2009\u2265\u200930\u00a0kg\/m<jats:sup>2<\/jats:sup>) individuals (59.8 (\u00b1\u20095.5) years, 53.9% women) from the Malm\u00f6 Diet and Cancer Cardiovascular Cohort were examined and IgM, IgG1 and IgG2 anti-PC were analyzed by ELISA. Individuals with at least one recorded history of hospitalization prior to study baseline were considered hospitalized obese (HO). Associations between IgM, IgG1 and IgG2 anti-PC and HO (n\u2009=\u200932)\/non-hospitalized obese (NHO) (n\u2009=\u200996), but also with metabolic syndrome and diabetes were analysed using logistic regressions. Both IgM and IgG1 anti-PC were inversely associated with HO, also after controlling for age and sex. When further adjusted for waist circumference, systolic blood pressure, glucose levels and smoking status, only IgG1 anti-PC remained significantly associated with HO. In multivariate models, each 1 standard deviation of increment in anti-PC IgG1 levels was inversely associated with prevalence of HO (odds ratio 0.57; CI 95% 0.33\u20130.98; p\u2009=\u20090.044). IgG2 anti-PC did not show any associations with HO. Low levels of IgM and IgG1 anti-PC are associated with higher risk of being a HO individual independent of sex and age, IgG1 anti-PC also independently of diabetes and metabolic syndrome. The anti-inflammatory properties of these antibodies may be related to inflammation in obesity and its complications.<\/jats:p>","DOI":"10.1038\/s41598-021-99615-z","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T13:24:52Z","timestamp":1634045092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibodies against phosphorylcholine in hospitalized versus non-hospitalized obese subjects"],"prefix":"10.1038","volume":"11","author":[{"given":"Amra","family":"Juji\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Korduner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Holm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Engstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bachus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Frosteg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Magnusson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"99615_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0140-6736(10)62037-5","volume":"377","author":"MM Finucane","year":"2011","unstructured":"Finucane, M. M. et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377, 557\u2013567 (2011).","journal-title":"Lancet"},{"key":"99615_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case\u2013control study. Lancet 364, 937\u2013952 (2004).","journal-title":"Lancet"},{"key":"99615_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11906-020-1027-7","volume":"22","author":"PM Nilsson","year":"2020","unstructured":"Nilsson, P. M., Korduner, J. & Magnusson, M. Metabolically Healthy Obesity (MHO)-new research directions for personalised medicine in cardiovascular prevention. Curr. Hypertens. Rep. 22, 18 (2020).","journal-title":"Curr. Hypertens. Rep."},{"key":"99615_CR4","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1172\/JCI129186","volume":"129","author":"GI Smith","year":"2019","unstructured":"Smith, G. I., Mittendorfer, B. & Klein, S. Metabolically healthy obesity: Facts and fantasies. J. Clin. Invest. 129, 3978\u20133989 (2019).","journal-title":"J. Clin. Invest."},{"key":"99615_CR5","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","volume":"53","author":"RA DeFronzo","year":"2010","unstructured":"DeFronzo, R. A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009. Diabetologia 53, 1270\u20131287 (2010).","journal-title":"Diabetologia"},{"key":"99615_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1741-7015-11-117","volume":"11","author":"J Frostegard","year":"2013","unstructured":"Frostegard, J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 11, 117 (2013).","journal-title":"BMC Med."},{"key":"99615_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clim.2016.04.007","volume":"166\u2013167","author":"M Rahman","year":"2016","unstructured":"Rahman, M. et al. IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms. Clin. Immunol. 166\u2013167, 27\u201337 (2016).","journal-title":"Clin. Immunol."},{"key":"99615_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrcardio.2009.55","volume":"6","author":"VZ Rocha","year":"2009","unstructured":"Rocha, V. Z. & Libby, P. Obesity, inflammation, and atherosclerosis. Nat. Rev. Cardiol. 6, 399\u2013409 (2009).","journal-title":"Nat. Rev. Cardiol."},{"key":"99615_CR9","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.orcp.2019.10.002","volume":"13","author":"J Korduner","year":"2019","unstructured":"Korduner, J., Bachus, E., Jujic, A., Magnusson, M. & Nilsson, P. M. Metabolically healthy obesity (MHO) in the Malm\u00f6 diet cancer study\u2014Epidemiology and prospective risks. Obes. Res. Clin. Pract. 13, 548\u2013554 (2019).","journal-title":"Obes. Res. Clin. Pract."},{"key":"99615_CR10","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti, K. G. et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640\u20131645 (2009).","journal-title":"Circulation"},{"key":"99615_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/cei.13441","volume":"201","author":"SK Samal","year":"2020","unstructured":"Samal, S. K., Qureshi, A. R., Rahman, M., Stenvinkel, P. & Frostegard, J. Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: Association with mortality. Clin. Exp. Immunol. 201, 94\u2013104 (2020).","journal-title":"Clin. Exp. Immunol."},{"key":"99615_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.atherosclerosis.2005.10.017","volume":"188","author":"J Su","year":"2006","unstructured":"Su, J. et al. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188, 160\u2013166 (2006).","journal-title":"Atherosclerosis"},{"key":"99615_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.rinim.2012.01.001","volume":"2","author":"R Fiskesund","year":"2012","unstructured":"Fiskesund, R. et al. IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL. Results Immunol. 2, 13\u201318 (2012).","journal-title":"Results Immunol."},{"key":"99615_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaut.2009.05.003","volume":"34","author":"U de Faire","year":"2010","unstructured":"de Faire, U. et al. Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: Effects on uptake of oxidized LDL in macrophages as a potential mechanism. J. Autoimmun. 34, 73\u201379 (2010).","journal-title":"J. Autoimmun."},{"key":"99615_CR15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.atherosclerosis.2008.07.009","volume":"203","author":"BG Sjoberg","year":"2009","unstructured":"Sjoberg, B. G. et al. Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis 203, 528\u2013532 (2009).","journal-title":"Atherosclerosis"},{"key":"99615_CR16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/HJR.0b013e32832a05df","volume":"16","author":"H Gronlund","year":"2009","unstructured":"Gronlund, H. et al. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur. J. Cardiovasc. Prev. Rehabil. 16, 382\u2013386 (2009).","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"99615_CR17","doi-asserted-by":"publisher","first-page":"R214","DOI":"10.1186\/ar3193","volume":"12","author":"C Anania","year":"2010","unstructured":"Anania, C. et al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res. Ther. 12, R214 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"99615_CR18","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/rheumatology\/ken120","volume":"47","author":"J Su","year":"2008","unstructured":"Su, J. et al. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford) 47, 1144\u20131150 (2008).","journal-title":"Rheumatology (Oxford)"},{"key":"99615_CR19","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1093\/ndt\/gfp309","volume":"24","author":"JJ Carrero","year":"2009","unstructured":"Carrero, J. J. et al. Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. Nephrol. Dial. Transpl. 24, 3454\u20133460 (2009).","journal-title":"Nephrol. Dial. Transpl."},{"key":"99615_CR20","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/art.34537","volume":"64","author":"J Vas","year":"2012","unstructured":"Vas, J., Gronwall, C., Marshak-Rothstein, A. & Silverman, G. J. Natural antibody to apoptotic cell membranes inhibits the proinflammatory properties of lupus autoantibody immune complexes. Arthritis Rheum. 64, 3388\u20133398 (2012).","journal-title":"Arthritis Rheum."},{"issue":"997\u20131005","key":"99615_CR21","first-page":"e1","volume":"58","author":"M Sobel","year":"2013","unstructured":"Sobel, M. et al. Low levels of a natural IgM antibody are associated with vein graft stenosis and failure. J. Vasc. Surg. 58(997\u20131005), e1-2 (2013).","journal-title":"J. Vasc. Surg."},{"key":"99615_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00392-014-0750-y","volume":"104","author":"CA Gleissner","year":"2015","unstructured":"Gleissner, C. A. et al. Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease. Clin. Res. Cardiol. 104, 13\u201322 (2015).","journal-title":"Clin. Res. Cardiol."},{"key":"99615_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.atherosclerosis.2015.10.024","volume":"243","author":"A Imhof","year":"2015","unstructured":"Imhof, A. et al. Long-term prognostic value of IgM antibodies against phosphorylcholine for adverse cardiovascular events in patients with stable coronary heart disease. Atherosclerosis 243, 414\u2013420 (2015).","journal-title":"Atherosclerosis"},{"key":"99615_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2015.12.009","volume":"170","author":"TG Nguyen","year":"2016","unstructured":"Nguyen, T. G. et al. Aberrant levels of natural IgM antibodies in osteoarthritis and rheumatoid arthritis patients in comparison to healthy controls. Immunol. Lett. 170, 27\u201336 (2016).","journal-title":"Immunol. Lett."},{"key":"99615_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/rheumatology\/kez264","volume":"59","author":"P L\u00f3pez","year":"2019","unstructured":"L\u00f3pez, P. et al. IgM anti-phosphorylcholine antibodies associate with senescent and IL-17+ T cells in SLE patients with a pro-inflammatory lipid profile. Rheumatology 59, 407\u2013417 (2019).","journal-title":"Rheumatology"},{"key":"99615_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/acr2.11127","volume":"2","author":"D Thiagarajan","year":"2020","unstructured":"Thiagarajan, D. et al. Immunoglobulin G1 antibodies against phosphorylcholine are associated with protection in systemic lupus erythematosus and atherosclerosis: Potential underlying mechanisms. ACR Open Rheumatol. 2, 344\u2013356 (2020).","journal-title":"ACR Open Rheumatol."},{"key":"99615_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2017.11.010","volume":"268","author":"J Sun","year":"2018","unstructured":"Sun, J. et al. IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors. Atherosclerosis 268, 36\u201348 (2018).","journal-title":"Atherosclerosis"},{"key":"99615_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jacc.2006.11.054","volume":"50","author":"G Caligiuri","year":"2007","unstructured":"Caligiuri, G. et al. Phosphorylcholine-targeting immunization reduces atherosclerosis. J. Am. Coll. Cardiol. 50, 540\u2013546 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"99615_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2005.11.033","volume":"189","author":"JR Faria-Neto","year":"2006","unstructured":"Faria-Neto, J. R. et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 189, 83\u201390 (2006).","journal-title":"Atherosclerosis"},{"key":"99615_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijpara.2014.12.006","volume":"45","author":"TR Aprahamian","year":"2015","unstructured":"Aprahamian, T. R. et al. The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model. Int. J. Parasitol. 45, 203\u2013207 (2015).","journal-title":"Int. J. Parasitol."},{"key":"99615_CR31","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.4049\/jimmunol.0900948","volume":"183","author":"Y Chen","year":"2009","unstructured":"Chen, Y. et al. Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J. Immunol. 183, 1346\u20131359 (2009).","journal-title":"J. Immunol."},{"key":"99615_CR32","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nm876","volume":"9","author":"CJ Binder","year":"2003","unstructured":"Binder, C. J. et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: Molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9, 736\u2013743 (2003).","journal-title":"Nat. Med."},{"key":"99615_CR33","doi-asserted-by":"publisher","first-page":"12120","DOI":"10.1038\/s41598-021-91679-1","volume":"11","author":"SK Samal","year":"2021","unstructured":"Samal, S. K., Frobert, O., Kindberg, J., Stenvinkel, P. & Frostegard, J. Potential natural immunization against atherosclerosis in hibernating bears. Sci. Rep. 11, 12120 (2021).","journal-title":"Sci. Rep."},{"key":"99615_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature21363","volume":"542","author":"GS Hotamisligil","year":"2017","unstructured":"Hotamisligil, G. S. Inflammation, metaflammation and immunometabolic disorders. Nature 542, 177\u2013185 (2017).","journal-title":"Nature"},{"key":"99615_CR35","first-page":"25","volume":"26","author":"A Booth","year":"2016","unstructured":"Booth, A., Magnuson, A., Fouts, J. & Foster, M. T. Adipose tissue: An endocrine organ playing a role in metabolic regulation. Horm. Mol. Biol. Clin. Invest. 26, 25\u201342 (2016).","journal-title":"Horm. Mol. Biol. Clin. Invest."},{"key":"99615_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-981-15-6407-9_8","volume":"1278","author":"D Bradley","year":"2021","unstructured":"Bradley, D., Shantaram, D., Smith, A. & Hsueh, W. A. Adipose tissue T regulatory cells: Implications for health and disease. Adv. Exp. Med. Biol. 1278, 125\u2013139 (2021).","journal-title":"Adv. Exp. Med. Biol."},{"key":"99615_CR37","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.4049\/jimmunol.1303035","volume":"192","author":"R Fiskesund","year":"2014","unstructured":"Fiskesund, R. et al. Naturally occurring human phosphorylcholine antibodies are predominantly products of affinity-matured B cells in the adult. J. Immunol. 192, 4551\u20134559 (2014).","journal-title":"J. Immunol."},{"key":"99615_CR38","doi-asserted-by":"crossref","unstructured":"Thiagarajan, D., Lundstr\u00f6m, S.L., Pershagen, G., Almqvist Malmros, C., Andolf, E., Hedman, A., Berg, O., Oparina, N. & Frosteg\u00e5rd, J. Antibodies against phosphorylcholine and malondialdehyde during the first two years of life. J. Immunol. 205, 2109\u20132116 (2020).","DOI":"10.4049\/jimmunol.2000437"},{"key":"99615_CR39","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1210\/jc.2017-02114","volume":"103","author":"F Ottosson","year":"2018","unstructured":"Ottosson, F. et al. Connection between BMI-related plasma metabolite profile and gut microbiota. J. Clin. Endocrinol. Metab. 103, 1491\u20131501 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"99615_CR40","doi-asserted-by":"crossref","unstructured":"Frosteg\u00e5rd, J., Tao, W., Rastam, L., Lindblad, U. & Lindeberg, S. Antibodies against phosphorylcholine among new Guineans compared to Swedes: An aspect of the hygiene\/missing old friends hypothesis. Immunol. Invest. 46, 59\u201369 (2017).","DOI":"10.1080\/08820139.2016.1213279"},{"key":"99615_CR41","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1749-6632.2009.04671.x","volume":"1173","author":"N Agmon-Levin","year":"2009","unstructured":"Agmon-Levin, N. et al. Antitreponemal antibodies leading to autoantibody production and protection from atherosclerosis in Kitavans from Papua New Guinea. Ann. N.Y. Acad. Sci. 1173, 675\u2013682 (2009).","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"99615_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1743-7075-4-7","volume":"4","author":"J Frostegard","year":"2007","unstructured":"Frostegard, J. et al. Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea. Nutr. Metab. (Lond.). 4, 7 (2007).","journal-title":"Nutr. Metab. (Lond.)."},{"key":"99615_CR43","first-page":"241","volume":"5","author":"MG Scott","year":"1988","unstructured":"Scott, M. G., Shackelford, P. G., Briles, D. E. & Nahm, M. H. Human-IGG subclasses and their relation to carbohydrate antigen immunocompetence. Diagn. Clin. Immunol. 5, 241\u2013248 (1988).","journal-title":"Diagn. Clin. Immunol."},{"key":"99615_CR44","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/424517","volume":"190","author":"HB Goldenberg","year":"2004","unstructured":"Goldenberg, H. B., McCool, T. L. & Weiser, J. N. Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. J. Infect. Dis. 190, 1254\u20131263 (2004).","journal-title":"J. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99615-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99615-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99615-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:33:34Z","timestamp":1670085214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99615-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["99615"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-99615-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"28 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JF is named as inventor on patents related to anti-PC. EB is employed by AstraZeneca. None for other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20246"}}